Navigation Links
Weikang Bio-Technology Announces Filing for NASDAQ Listing
Date:6/22/2010

HARBIN, China, June 22 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that the Company had filed an application to list its common stock on the NASDAQ Capital Market.

"This is an important milestone for Weikang as we continue to expand our business and broaden our market penetration," commented Mr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group. "NASDAQ is a prestigious senior exchange that is well suited for rapidly growing companies such as Weikang that meets its stringent listing requirements. If approved, the listing can help to broaden the Company's shareholder base, provide greater trading liquidity and raise the Company's profile in the investment community."

Weikang believes it satisfies the majority of the listing qualifications associated with this application. The application is subject to review by NASDAQ's Listing Qualifications Department for compliance with all NASDAQ Capital Market requirements. The Company's common stock will continue to trade on the OTC Bulletin Board under its current symbol, WKBT, until the Company is notified of its acceptance.

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com .

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

    Company contact:

     Ren Hu, VP of Finance
     Weikang Bio-Technology Group Co., Inc.
     US Tel:     +1-201-887-0415
     China cell: +86-137-1872-8163
     Email:      arenhu@gmail.com

    Investors Relation contact:

     John Marco, Partner, Elite IR
     Tel:   +1-310-819-2948
     Email: John.marco@elite-ir.com

     Leslie J. Richardson, Partner, Elite IR
     Tel:   +852-3183-0283
     Email: Leslie.richardson@elite-ir.com


'/>"/>
SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Weikang Bio-Technology Reports First Quarter 2010 Financial Results
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for ... Care Association of America (HCAOA). This agreement allows HCAOA members to receive special ... as discounts on Accreditation University (AU) educational resources that help prepare HCAOA members ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Horizon Blue Cross ... the company’s credit rating of “A” and its outlook as “stable.” At the same ... reserves, which have fallen in recent years, dip below “capital adequacy” thresholds required for ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... Replace tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent ... rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a program ... delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in ... and decide to donate. , “Women’s Hospital at Renaissance has been a collection ...
(Date:4/28/2017)... ... April 28, 2017 , ... Bill Howe started his sewer and drain ... After Tina Howe joined the team, the Bill Howe brand was born and they ... rates, and giving back to the San Diego community in which they worked, lived ...
Breaking Medicine News(10 mins):